HLVX vs. TECX, EOLS, CMPS, PRTA, REPL, ARCT, RGNX, MBX, ATXS, and YMAB
Should you be buying HilleVax stock or one of its competitors? The main competitors of HilleVax include Tectonic Therapeutic (TECX), Evolus (EOLS), COMPASS Pathways (CMPS), Prothena (PRTA), Replimune Group (REPL), Arcturus Therapeutics (ARCT), REGENXBIO (RGNX), MBX Biosciences (MBX), Astria Therapeutics (ATXS), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "pharmaceutical products" industry.
HilleVax vs. Its Competitors
HilleVax (NASDAQ:HLVX) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.
Tectonic Therapeutic's return on equity of -30.13% beat HilleVax's return on equity.
HilleVax currently has a consensus price target of $2.00, indicating a potential downside of 2.91%. Tectonic Therapeutic has a consensus price target of $80.33, indicating a potential upside of 206.85%. Given Tectonic Therapeutic's stronger consensus rating and higher possible upside, analysts clearly believe Tectonic Therapeutic is more favorable than HilleVax.
In the previous week, HilleVax and HilleVax both had 2 articles in the media. Tectonic Therapeutic's average media sentiment score of 1.64 beat HilleVax's score of 0.00 indicating that Tectonic Therapeutic is being referred to more favorably in the news media.
86.4% of HilleVax shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 24.9% of HilleVax shares are owned by insiders. Comparatively, 38.0% of Tectonic Therapeutic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
HilleVax has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Tectonic Therapeutic has a beta of 3.27, indicating that its stock price is 227% more volatile than the S&P 500.
Tectonic Therapeutic is trading at a lower price-to-earnings ratio than HilleVax, indicating that it is currently the more affordable of the two stocks.
Summary
Tectonic Therapeutic beats HilleVax on 10 of the 13 factors compared between the two stocks.
Get HilleVax News Delivered to You Automatically
Sign up to receive the latest news and ratings for HLVX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HLVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HilleVax Competitors List
Related Companies and Tools
This page (NASDAQ:HLVX) was last updated on 8/22/2025 by MarketBeat.com Staff
MarketBeat All Access